Antipsychotic medications are among the most important—and sometimes most misunderstood—medications used in psychiatry. Their best-known role is treating psychotic symptoms such as hallucinations and delusions, but their place in modern psychiatric care is actually much broader and more nuanced than that.

For some individuals, these medications are used temporarily during an acute episode. For others, treatment may continue for months or years. In certain chronic conditions, long-term treatment may be absolutely necessary to reduce the risk of severe symptoms returning.

That is precisely why choosing an antipsychotic is rarely as simple as asking which medication is “strongest.” The far more useful question is: Which medication offers this particular person the best possible balance between symptom control and tolerability?

How Antipsychotic Treatment Changed Psychiatry

Modern antipsychotic treatment officially began in the early 1950s with the introduction of chlorpromazine. Its arrival was a major medical turning point because, for the first time, physicians finally had a medication capable of substantially reducing severe psychotic symptoms in many patients.

Since then, the field of psychiatry has gained a much larger and more diverse range of medications. This variety matters deeply because people do not respond to every antipsychotic in the exact same way. A medication that works exceptionally well for one person may produce troublesome side effects or insufficient clinical improvement in another.

The ultimate goal is therefore not simply to prescribe an antipsychotic. It is to find a highly individualized treatment that controls symptoms while allowing the person to function as normally and comfortably as possible.

What Do Antipsychotics Actually Treat?

Antipsychotics are especially critical in conditions involving psychosis. They can effectively reduce hallucinations, delusions, severe disorganization, and other profound symptoms that interfere with a person's ability to understand and respond to reality.

Depending on the specific medication's profile, antipsychotics may also be utilized in the treatment of bipolar disorder and, in certain cases, as an adjunctive treatment for major depressive disorder or other complex psychiatric conditions.

Some antipsychotics can also safely reduce severe agitation. Sedating properties may sometimes be useful when a patient's agitation is intense, but sedation itself should never be confused with the core antipsychotic effect.

Whenever treatment continues beyond the immediate medical crisis, a patient's quality of life becomes incredibly important. A person should ideally be able to work, study, communicate, maintain meaningful relationships, and carry out everyday activities without being unnecessarily slowed down or hindered by their medication.

Dopamine Matters—but the Story Is More Complicated

Many traditional antipsychotic medications work largely by blocking dopamine D2 receptors in the brain. This specific mechanism is closely connected with their ability to reduce positive psychotic symptoms.

Second-generation, often called atypical, antipsychotics generally feature a more complex receptor profile and commonly affect both dopamine and serotonin signaling pathways. Some newer medications—including aripiprazole, brexpiprazole, and cariprazine—act as partial dopamine receptor agonists rather than simply blocking those receptors entirely. This mechanism helps to stabilize dopamine levels, reducing them where they are too high and boosting them where they are too low.

This is sometimes described informally as a newer or “third-generation” group, although that specific terminology is not universally used in the medical community.

There is another major reason not to say that every modern antipsychotic simply blocks dopamine: antipsychotic pharmacology continues to rapidly evolve. In 2024, the FDA approved the first schizophrenia treatment in this class that targets cholinergic receptors rather than dopamine receptors.

So, the modern pharmacological picture is significantly more complicated than the old idea that all antipsychotics work in essentially the same way.

First- and Second-Generation Antipsychotics

Antipsychotics are most commonly discussed as first-generation and second-generation medications.

First-generation antipsychotics have a long, proven history of effective treatment, particularly for positive psychotic symptoms such as severe hallucinations and delusions. However, some of them have a substantially greater tendency to produce movement-related side effects.

Second-generation medications successfully expanded treatment choices and often present different movement-related risks. But describing them simply as “safer” across the board can be misleading.

Some second-generation antipsychotics carry significant metabolic effects, while others may cause restlessness, sedation, prolactin elevation, or movement symptoms.

In other words, the medication's unique individual profile matters much more than the broad label attached to its generation.

Movement-Related Side Effects

One critical group of adverse effects is officially known as extrapyramidal symptoms, or EPS. Because the risk of these problems is not identical with every antipsychotic, treatment must be closely individualized and monitored. These symptoms include:

• Akathisia: This creates an intensely uncomfortable feeling of inner restlessness. A person may feel utterly unable to sit still, repeatedly move their legs, pace the room, or constantly change position. This can be extremely uncomfortable and should not simply be mistaken for worsening anxiety or agitation.
• Acute dystonia: This involves sudden, involuntary muscle contractions. These painful spasms may affect the face, jaw, neck, eyes, or other parts of the body.
• Drug-induced parkinsonism: This can look very different from other side effects. Instead of excessive movement, a person may become physically slower and stiffer, develop a noticeable tremor, or observe that their movements feel far less natural.
• Tardive dyskinesia: This typically develops after longer-term exposure to dopamine-blocking medications. It can cause repetitive, involuntary movements, very often involving the mouth, tongue, face, trunk, or limbs.

Weight, Blood Sugar, and Cholesterol

Movement symptoms are only part of the clinical discussion.

Some antipsychotics can significantly increase appetite and body weight or negatively affect blood glucose and cholesterol levels. These metabolic changes are particularly crucial to monitor during long-term treatment because they can eventually impact cardiovascular health and overall physical well-being.

Again, there is no single metabolic profile that applies to the entire class of drugs. Some medications carry a substantially greater risk of weight gain and metabolic abnormalities than others.

For this precise reason, clinicians must monitor body weight and appropriate laboratory measures such as fasting glucose and lipids. If significant changes appear, the treatment plan can be actively reconsidered rather than simply accepting those negative changes as inevitable.

Proper nutrition, appropriate physical activity, and the careful management of other medical risk factors must also become a central part of the overall treatment plan.

What About Prolactin?

Some antipsychotics can artificially raise the level of prolactin, a hormone whose release is directly influenced by dopamine.

When prolactin becomes significantly elevated in the bloodstream, possible physical effects include menstrual cycle changes, breast enlargement or spontaneous milk production, reduced sexual interest, erectile or other sexual difficulties, and broader reproductive problems.

Not everyone with an elevated laboratory value develops physical symptoms, and different antipsychotics affect prolactin levels very differently.

Some medications are relatively likely to raise it, while dopamine partial agonists such as aripiprazole generally boast a much lower risk and may sometimes even be used to reduce prolactin that has been elevated by another antipsychotic.

The medical response depends entirely on the individual situation. A clinician will carefully consider the dose, the medication itself, the patient's symptoms, the laboratory findings, and the fundamental reason the antipsychotic is being prescribed before deciding whether any medication change is needed.

Sedation Can Help—or Become a Problem

Sedation is another medication effect that requires proper context.

During a period of severe agitation or acute behavioral disturbance, a calming, sedating effect may sometimes be highly useful and protective. But when a person is psychiatric stable and actively trying to return to their ordinary life, excessive daytime sleepiness can become a serious, debilitating burden.

Someone who is technically improving on paper but can barely stay awake at their job, concentrate in a classroom, or participate in their family life has not yet reached the best possible treatment balance.

This is why tolerability is not a minor issue—it is a foundational component of successful psychiatric treatment.

There Is No Universal “Best” Antipsychotic

The field of psychiatry currently has no single antipsychotic medication that is ideal for everyone.

A medication may be highly effective at stopping psychosis but entirely unsuitable because of severe movement symptoms. Another may cause far too much weight gain. Yet another may produce intolerable restlessness or excessive sleepiness. A medication that causes terrible problems for one person may be very well tolerated and life-saving for someone else.

This is precisely why having many diverse treatment options is so incredibly valuable.

Modern psychiatric prescribing is increasingly about actively balancing several vital factors at once: symptom improvement, physical health, manageable side effects, previous treatment responses, personal preferences, and the person's ability to navigate everyday life.

For individuals who require long-term treatment, that delicate balance becomes especially important. The core purpose of medication is not merely to suppress psychiatric symptoms at any physical cost. Effective treatment should also make it possible, as far as the underlying illness allows, to remain fully engaged with work, education, relationships, and ordinary daily life.

Finding that perfect balance may require careful dosage adjustments, frequent monitoring, and sometimes completely changing medications. But the broad range of treatments available today gives clinicians far more opportunities than ever before to find an option that is both highly effective and reasonably well tolerated.

This article is intended for general educational purposes only and does not replace individualized medical advice. Antipsychotic medications should not be started, stopped, or changed without direct guidance from a prescribing healthcare professional.

References

• Keepers, G. A., Fochtmann, L. J., Anzia, J. M., et al. (2020). The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. American Journal of Psychiatry, 177(9), 868–872. DOI: 10.1176/appi.ajp.2020.177901. Provides evidence-based recommendations for schizophrenia treatment, including the use of antipsychotic medication and the importance of monitoring effectiveness and adverse effects.
• Stroup, T. S., & Gray, N. (2018). Management of common adverse effects of antipsychotic medications. World Psychiatry, 17(3), 341–356. DOI: 10.1002/wps.20567. Reviews major antipsychotic adverse effects, including akathisia, parkinsonism, sedation, weight gain, metabolic abnormalities, hyperprolactinemia, and sexual dysfunction, as well as approaches to minimizing them.
• López-Muñoz, F., Álamo, C., Cuenca, E., Shen, W. W., Clervoy, P., & Rubio, G. (2005). History of the discovery and clinical introduction of chlorpromazine. Annals of Clinical Psychiatry, 17(3), 113–135. DOI: 10.1080/10401230591002002. Describes the discovery and introduction of chlorpromazine in the early 1950s and its major role in the development of modern psychopharmacology.
• Frankel, J. S., & Schwartz, T. L. (2017). Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Therapeutic Advances in Psychopharmacology, 7(1), 29–41. DOI: 10.1177/2045125316672136. Discusses aripiprazole, brexpiprazole, and cariprazine and explains how dopamine D2 partial agonism differs from conventional dopamine receptor antagonism.
• U.S. Food and Drug Administration. (2025). Olanzapine prescribing information. The prescribing information documents metabolic effects including hyperglycemia, dyslipidemia, and weight gain, as well as tardive dyskinesia, hyperprolactinemia, sedation, akathisia, and other clinically relevant adverse effects.
• U.S. Food and Drug Administration. (2024). FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia. Documents the 2024 approval of xanomeline/trospium for schizophrenia in adults and explains that it was the first FDA-approved antipsychotic for schizophrenia to target cholinergic receptors rather than dopamine receptors.